Ankur Drugs signs IPR agreement with Labtech

New Delhi, Mar 4: Ankur Drugs and Pharma Ltd said it has signed an agreement with Labtech of GMBH, Germany and Applied Pharma Research (APR) for exclusive intellectual property rights for a novel technology.

For requisite machines and equipment, the company has partnered with Optimags, a special coating line in Germany and Siebler (Romaco group) packing line for its products, Ondansetrone, Donepezil Hcl, Ketotifen Fumarate, Baclofe, Rivastigmine, Sildenafil Citrate, Glimepiride and Olanzapine.

The exclusive manufacturing rights have been granted for initial 15 years in India, Bangladesh, Sri Lanka, Pakistan and Afghanistan, a statement said on Friday.

Commercial launch of these products is expected to start in January next year.

It has also inked technology tied-ups for manufacturing and marketing rights of 'Fantanyl' in India, Bangladesh, Pakistan, Nepal, Afghanistan, Bhutan, Brunei, Indonesia, Cambodia, Casachstan, North Korea, Laos, Malaysia, Maldives.

UNI